Practice Areas / Dangerous Drugs Lawsuits
Elmiron Lawsuits
Have you been prescribed Elmiron for the treatment of a urinary tract infection (UTI) or interstitial cyctisis? Were you thereafter diagnosed with vision problems related to macula or retina degeneration or maculopathy?
Elmiron, a drug that is widely prescribed for treating pain and discomfort associated with interstitial cystitis (IC), has recently come under fire for possibly causing retinal damage and eventual vision loss. The prescription drug has been linked to the development of pigmentary maculopathy amongst other vision problems when used for long-term treatment of IC.
Elmiron lawsuits claim that Janssen Pharmaceuticals, the manufacturers of Elmiron, failed to warn physicians and the public of the risks associated with the use of the drug for long-term treatment.
What is Elmiron?
Elimiron, pentosan polysulfate sodium (PPS), is an FDA-approved medication approved for treating bladder discomfort and pain associated with the chronic condition interstitial cystitis (IC). Elmiron is taken daily by patients and is the only oral medication approved for the treating IC. It is classified as a urinary analgesic or pain reliever as well as a weak anticoagulant or blood thinner.
The medication acts by forming a thin layer of protection on the inside surface of the bladder wall. This protects the bladder wall from irritation and other harmful substances that may be present in urine. This drug is widely prescribed for treating discomfort and pain related to IC in both men and women. It is commonly used for long-term management. In fact, many patients end up taking the drug for years.
Elmiron lawsuits claim that Janssen Pharmaceuticals, the manufacturers of Elmiron, failed to warn physicians and the public of the risks associated with the use of the drug for long-term treatment.